Objective:To explore the effect of DC-CIK in combined with chemotherapy on the immunological function in patients with advanced non-small cell lung cancer (NSCLC). Methods:A total of 86 patients with NSCLC who were ad...Objective:To explore the effect of DC-CIK in combined with chemotherapy on the immunological function in patients with advanced non-small cell lung cancer (NSCLC). Methods:A total of 86 patients with NSCLC who were admitted in our hospital were included in the study and randomized into the observation group and the control group with 43 cases in each group. The patients in the two groups were given routine chemotherapy. On this basis, the patients in the observation group were given DC-CIK cellular immunotherapy. The patients in the two groups were treated for 3 courses. The peripheral blood T lymphocytes and cytokines after treatment in the two groups were compared. The clinical efficacy and adverse reactions in the two groups were evaluated.Results:The total effective rate and disease control rate after treatment in the observation group were slightly higher than those in the control group, but the comparison between the two groups was not statistically significant. CD8+ after treatment in the observation group was significantly reduced, while CD3+, CD4+, and CD4+/CD8+ were significantly elevated when compared with before treatment. CD3+ and NK contents, and CD4+/CD8+ after treatment in the observation group were significantly higher than those in the control group. IFN-γ, IL-4, TNF-α levels, and Th1/Th2 after treatment in the observation group were significantly higher than those in the control group, while TGF-β level was significantly lower than that in the control group. The occurrence rate of nausea and vomiting, and liver and renal function damage in the observation group was significantly lower than that in the control group, but the median progression free survival (PFS) was significantly longer than that in the control group, while the comparison of median overall survival (OS) between the two groups was not statistically significant, and 2-year survival rate was significantly higher than that in the control group.Conclusions: DC-CIK in combined with chemotherapy can correct the immunologic disorder in patients with advanced NSCLC, and strengthen the anti-tumor effect.展开更多
文摘Objective:To explore the effect of DC-CIK in combined with chemotherapy on the immunological function in patients with advanced non-small cell lung cancer (NSCLC). Methods:A total of 86 patients with NSCLC who were admitted in our hospital were included in the study and randomized into the observation group and the control group with 43 cases in each group. The patients in the two groups were given routine chemotherapy. On this basis, the patients in the observation group were given DC-CIK cellular immunotherapy. The patients in the two groups were treated for 3 courses. The peripheral blood T lymphocytes and cytokines after treatment in the two groups were compared. The clinical efficacy and adverse reactions in the two groups were evaluated.Results:The total effective rate and disease control rate after treatment in the observation group were slightly higher than those in the control group, but the comparison between the two groups was not statistically significant. CD8+ after treatment in the observation group was significantly reduced, while CD3+, CD4+, and CD4+/CD8+ were significantly elevated when compared with before treatment. CD3+ and NK contents, and CD4+/CD8+ after treatment in the observation group were significantly higher than those in the control group. IFN-γ, IL-4, TNF-α levels, and Th1/Th2 after treatment in the observation group were significantly higher than those in the control group, while TGF-β level was significantly lower than that in the control group. The occurrence rate of nausea and vomiting, and liver and renal function damage in the observation group was significantly lower than that in the control group, but the median progression free survival (PFS) was significantly longer than that in the control group, while the comparison of median overall survival (OS) between the two groups was not statistically significant, and 2-year survival rate was significantly higher than that in the control group.Conclusions: DC-CIK in combined with chemotherapy can correct the immunologic disorder in patients with advanced NSCLC, and strengthen the anti-tumor effect.
